ERNA Ernexa Therapeutics - on track for ind submission Q3 2026 and phase 1 trial Q4 2026 - Plans ind submission for Q3 2026; phase 1 trial e

ERNA Ernexa Therapeutics - on track for ind submission Q3 2026 and phase 1 trial Q4 2026 - Plans ind submission for Q3 2026; phase 1 trial expected to begin Q4 2026 - Erna-101 plus anti-pd-1 achieves complete tumor clearance in two-thirds of treated animals - No complete tumor clearance observed with erna-101 or anti-pd-1 monotherapy